Families Hit Back At GSK'S Zofran Fraud Dismissal Bid

Law360, New York (January 4, 2017, 2:14 PM EST) -- Plaintiffs in a multidistrict litigation against GlaxoSmithKline PLC told a Massachusetts federal court Tuesday that they adequately set out off-label fraud claims in master complaints linking the anti-nausea drug Zofran to birth defects.

Although the master complaints lack granular detail about the alleged fraud, they lay out exactly what is needed at this stage in the MDL, which involves hundreds of people claiming their babies were injured or died as a result of prenatal exposure to the drug, according to the parents' opposition brief.

The filing...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation


Case Number

1:15-md-02657

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Judge

F. Dennis Saylor, IV

Date Filed

October 13, 2015

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.